| Entry |
|
|---|
| Name |
Ensovibep (INN);
Ensovibep (genetical recombination) (JAN) |
|---|
| Formula |
C3730H6063N1067O1166
|
|---|
| Exact mass |
84461.7936
|
|---|
| Mol weight |
84511.51
|
|---|
| Sequence |
GSDLGKKLLE AARAGQDDEV RELLKAGADV NAKDYFSHTP LHLAARNGHL KIVEVLLKAG
ADVNAKDFAG KTPLHLAANE GHLEIVEVLL KAGADVNAQD IFGKTPADIA ADAGHEDIAE
VLQKAAGSPT PTPTTPTPTP TTPTPTPTGS DLGKKLLEAA RAGQDDEVRE LLKAGADVNA
KDYFSHTPLH LAARNGHLKI VEVLLKAGAD VNAKDFAGKT PLHLAANEGH LEIVEVLLKA
GADVNAQDIF GKTPADIAAD AGHEDIAEVL QKAAGSPTPT PTTPTPTPTT PTPTPTGSDL
GKKLLQAARA GQLDEVRELL KAGADVNAKD REGITPLHLA AQHGHLEIVE VLLKAGADVN
AKDVWGRTPL HLAAWQGHLE IVEVLLKAGA DVNAKDLAGA TPLHVAALYG HLEIVEVLLK
AGADVNAQDK SGKTPADLAA RAGHQDIAEV LQKAAGSPTP TPTTPTPTPT TPTPTPTGSD
LGKKLLQAAR AGQLDEVREL LKAGADVNAK DREGKTPLHV AAQEGHLEIV EVLLKAGADV
NAKDVWGRTP LHLAAWIGHL EIVEVLLKAG ADVNAKDVSG ATPLHAAALH GHLEIVEVLL
NAGADVNAQD KSGKTPADLA ARAGHQDIAE VLQKAAGSPT PTPTTPTPTP TTPTPTPTGS
DLGKKLLQAA RAGQLDEVRE LLKAGADVNA KDQEGITPLH VAAHQGHLEI VEVLLKAGAD
VNAKDVWGRT PLHLAAWRGH LEIVEVLLKA GADVNAKDHA GATPLHAAAL SGHLEIVEVL
LKAGADVNAQ DKSGKTPADL AARAGHQDIA EVLQAA |
|---|
| Type |
Peptide |
|---|
| Class |
Antiviral
DG03174 Anti-SARS-CoV-2 agent
|
|---|
| Efficacy |
Antiviral |
|---|
| Comment |
ankyrin repeat
|
|---|
| Target |
SARS-CoV-2 spike glycoprotein [KO: K24152] |
|---|
| Pathway |
| ko05171 | Coronavirus disease - COVID-19 |
|
|---|
| Brite |
Drug groups [BR:br08330]
Antiviral
DG03174 Anti-SARS-CoV-2 agent
D12406 Ensovibep
Antimicrobials [BR:br08307]
Antivirals
Entry, fusion or uncoating inhibitor
Coronavirus spike protein
D12406 Ensovibep (INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
